A budget impact analysis of budesonide/formoterol in patients with mild asthma in Egypt.

Conclusion: Budesonide/formoterol in mild asthma instead of salbutamol produces better patient outcomes, decreases total costs with increases in drug cost offset by reductions in non-drug costs due to fewer exacerbations. Budesonide/formoterol is a budget saving option for guideline-directed treatment, from the economic perspective of the payer and the health perspective of the patient. PMID: 31298593 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research